1. Home
  2. MITQ vs VRAX Comparison

MITQ vs VRAX Comparison

Compare MITQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.52

Market Cap

6.2M

ML Signal

HOLD

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$2.28

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
VRAX
Founded
N/A
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
2.1M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MITQ
VRAX
Price
$0.52
$2.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
★ 107.0K
27.7K
Earning Date
05-15-2026
06-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 70.00
N/A
EPS
N/A
★ N/A
Revenue
★ $20,139,000.00
N/A
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
$58.00
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.42
$0.10
52 Week High
$1.12
$13.19

Technical Indicators

Market Signals
Indicator
MITQ
VRAX
Relative Strength Index (RSI) 47.13 38.23
Support Level $0.53 $2.15
Resistance Level $0.64 $3.01
Average True Range (ATR) 0.07 0.18
MACD -0.01 -0.02
Stochastic Oscillator 26.63 16.13

Price Performance

Historical Comparison
MITQ
VRAX

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: